It was observed that beyond the beneficial therapeutic effect in T2DM by inhibition of human alpha-glucosidase and reduced absorption of dietary carbohydrates, the drug can also inhibit gut bacteria alpha-glucosidase, with an impact on bacterial ability to metabolize carbohydrates, and can be a cause of fluctuation in the structure of human microbiota [99]. Here, GAA is linked to type 2 diabetes mellitus.